Attendee search 

COMPANY PRESCRIPTION;

Kissei America, Inc is the US subsidiary of Kissei Pharma, one of the Japanese medium-sized pharma companies spending about 20% of revenue to its R&D effort. 

 Kissei is actively seeking for in-licensing, out-licensing and other business development opportunities for new drugs. 

For in-licensing, Kissei's primary focus is the territory of Japan and the therapeutic fields of urology, dialysis management/kidney disease, women's health, opthalmology and certain diseases with unmet medical needs.

For out-licensing, Kissei is actively seeking partners for several new chemical entities for the territory outside Japan.   Such out-licensing opportunities include agents for endometriosis/fibroid, diabetes, Parkinson's disease, gout/hyperuricemia and kidney stone in various stage of development.

PIPELINE PRODUCT;

1.       NAME ; Mitiglinide

DESCRIPTION     ; Mitiglinide is a short-acting insulin secretagogue for type II diabetes.  The  

                               agent has been already on the market in Japan and some Asian countries. 

                               The product is available for licensing in certain countries outside Asian

                                countries.

PHASE                    ; Market

INDICATION        ; Type II diabetes

2.       NAME ; Remoglifozin

DESCRIPTION     ; Remogliflozin is an SGLT2 inhibitor available for licensing in certain

                                countries.

PHASE                    ; Phase ll, lla, llb

INDICATION       ; Diabetes

3.       NAME; KUL-7211

DESCRIPTION     ; KUL-7211 is a beta 2/3 dual agonist, targeting the facilitation of kidney   

                                stone passage, available for licensing.

PHASE                   ;  Phase ll, lla, llb

INDICATION       ;  Kidney Stone

4.       NAME ; KLH-2109

DESCRIPTION         ; KLH-2109 is on oral GnRH antanogist available for licensing

PHASE                       ; Phase ll, lla, llb

INDICATION           ; Endometriosis, Uterine Fibroids

5.       NAME ; KGA-3235

DESCRIPTION         ; KGA-3235 is an SGLT1 inhibitor available for licensing in certain Asian

                                    countries.

PHASE                       ; Phase l

INDICATION           ;  Diabetes

6.       NAME ; KOM-1962

DESCRIPTION         ; KOM-1962 is a novel and improved COMT inhibitor available for

                                    licensing.

PHASE                       ; Preclinical

INDICATION           ; Parkinson’s Disease

7.       NAME ; KUX-0511

DESCRIPTION         ; KUX-0511 is the agent to be developed for gout and hyperuricemia

                                    through  decreasing  formation of uric acid and uricosuric effect, and                      

                                    available for  licensing.

PHASE                       ; Phase l

INDICATION           ; Gout and Hyperuricemia

ORCHID, in conjunction with its Indian R&D arm, USA drug discovery subsidiary, Bexel Pharmaceuticals Inc, and USA affiliate, Diakron Pharmaceuticals Inc, has new Drug Discovery programs in therapeutic areas of metabolic disorders, cardio-vascular, oncology, inflammation and anti-infectives.
It brings forth a rich pipeline of NCEs for out-licensing and recently received a milestone for an ongoing anti-infective collaboration with MERCK.
Orchid Chemicals & Pharmaceuticals Ltd. (ORCHID), an Indian Pharmaceutical company, of global standing and innovation is fuelling growth through R&D of novel small molecules and new pharmaceutical products backed by scientific, technical and manufacturing competencies and global intellectual property management.
ORCHID operates in business domains of APIs, finished dosage forms (Generics), New Drug Discovery(NCE), & Custom Research & Manufacturing Services (crams), while pursuing biotechnology based green chemistry initiatives and is assessing entry into Bio-Pharmaceuticals (bio-betters).
Orchid continues to expand its patent technologies, new chemical entities/product and services through various business propositions.

Accucaps Industries specializes in soft gel formulations and operates a full R&D organization, developing and supporting projects from early research to life cycle management. We are continually engaged with potential partners in exploring how our broad therapeutic portfolio, formulation, clinical development and manufacturing expertise combined with strong customer relationships, can yield mutually beneficial business relationships.

Our Product Innovation team has developed technologies which may enhance bioavailability through advanced technologies incorporated into the design of various formulation solutions within soft gel capsules.  Some of these technologies may assist your organization in maintaining their leading position with their top products through additional lifecycle options.